BioPhia Consulting Inc.
BioPhia Home
The Team
May, 2016
June, 2016
September, 2016
November, 2016
February, 2017
March, 2017
June, 2017
August, 2017
September, 2017
This is the category1 description.
CDER Update May/June 2017
9/8/2017 9:20:48 AM

·         Activities Report of the Generic Drug Program (FY 2017) 



·         Office of Pharmaceutical Quality - Emerging Technology Program promotes the adoption of innovative approaches to pharmaceutical manufacturing.




This guidance describes the process through which prospective generic drug applicants submit pre-submission facility correspondence (PFC) in advance of priority generic drug submissions.




CBER Update May/June 2017
9/8/2017 9:19:32 AM

·         February 8, 2017 Transcript - Identification and Characterization of the Infectious Disease Risks of Human Cells, Tissues, and Cellular and Tissue-based Products (PDF - 2.7MB) 


·         February 9, 2017 Transcript - Identification and Characterization of the Infectious Disease Risks of Human Cells, Tissues, and Cellular and Tissue-based Products (PDF - 1.4MB) 


·         Use of Symbols in Labeling 


·         Submitting Field Alert Reports (FARs) to CBER 

CDRH Update May/June 2917
9/8/2017 9:17:48 AM




SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Use of  Electronic Records and Electronic Signatures in Clinical Investigations  under our regulations--Questions and Answers.'' The draft guidance provides guidance to sponsors, clinical investigators, institutional review boards (IRBs), contract research organizations (CROs), and other  interested parties on the use of electronic records and electronic  signatures under our regulations in clinical investigations of medical  products. The draft guidance expands upon recommendations in the guidance for industry entitled ``Part 11, Electronic Records;  Electronic Signatures--Scope and Application'' issued in August 2003  (referred to as the 2003 part 11 guidance) for recommendations that  pertain to FDA-regulated clinical investigations conducted under our  regulations.
To ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by August 21, 2017.



The Food and Drug Administration (FDA, the Agency, or we) is  announcing the following public workshop entitled ``Antimicrobial  Susceptibility and Resistance: Addressing Challenges of Diagnostic  Devices.'' The purpose of this workshop is to discuss potential  scientific and regulatory challenges associated with developing  traditional antimicrobial susceptibility testing (AST) devices and  devices that detect antimicrobial resistance markers by molecular or  novel diagnostic technologies, and to provide an overview of relevant  provisions of the 21st Century Cures Act that may impact the  development of such devices. Public input and feedback gained through  this workshop will aid in the development of science-based approaches  to regulatory decisionmaking regarding traditional and novel AST  devices. Further, this workshop will explore opportunities for the  efficient development and evaluation of AST devices, which may lead to  better patient care and reduce antimicrobial resistance through  improved antibiotic stewardship.  DATES: The public workshop will be held on September 13, 2017, from  8:30 a.m. to 5 p.m.


SUMMARY: The Food and Drug Administration (FDA or Agency) has  determined that it is necessary for manufacturers of certain reusable  medical devices to include in their premarket notifications (510(k)s)  instructions for use which have been validated and validation data  regarding cleaning, disinfection, and sterilization, for which a  substantial equivalence determination may be based. This notice  includes a list of these reusable devices that will require validated  instructions for use and validation data in their premarket  notification. FDA is publishing this list in accordance with the  requirements established by the 21st Century Cures Act. This action  ensures that the premarket requirements for these device types are  clear and predictable which facilitates more efficient review of these  510(k)s.  DATES: These actions are effective on August 8, 2017.


·         Federal Register: Humanitarian Use Devices; 21st Century Cures Act; Technical Amendmen

The Food and Drug Administration (FDA) is amending regulations to reflect changes recently enacted into law by the 21st Century Cures  Act. Specifically, certain requirements related to humanitarian device exemptions (HDEs) and institutional review boards (IRBs) for devices  have changed. This action is being taken to align the regulations with the Federal Food, Drug, and Cosmetic Act (the FD&C Act) as amended.

CDER Updates March/April 2017
6/2/2017 1:43:19 PM



Update to Guidance

Section I. Introduction

• Paragraph added describing rationale for changing timetable for required master file submissions in eCTD from 24 months to 36 months.

Section III.B. Timetable for Implementation of Electronic Submission Requirements

·         Updated to reflect that the requirement for master files to be filed electronically takes place 36 months after May 5, 2015.

Example of timetable updated to reflect actual timetable for the implementation of the electronic submissions requirement.
CBER Updates March/April 2017
6/2/2017 1:41:18 PM





The Food and Drug Administration (FDA) issued a final rule, Use of Symbols in Labeling, June 15, 2016, that became effective September 13, 2016. The final rule permits the use of symbols in all medical device labeling without adjacent explanatory text (referred to as "stand-alone symbols") if certain requirements are met. The final rule also specifies that the use of symbols, accompanied by adjacent explanatory text continues to be permitted. The final rule seeks to harmonize the U.S. device labeling requirements for symbols with international regulatory requirements.

Below is a list of resources on the use of symbols in labeling:

·         Final Rule: Use of Symbols in Labeling

·         Frequently Asked Questions

FDA Voice: Using Symbols to Convey Information in Medical Device Labeling
12 items total 1  2  3 

<< All categories
BioPhia Home
The Team